<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113317</url>
  </required_header>
  <id_info>
    <org_study_id>FakultasKUI</org_study_id>
    <nct_id>NCT04113317</nct_id>
  </id_info>
  <brief_title>Granulocyte-Colony Stimulating Factor (G-CSF) as Optimizing Therapy for Pediatric Liver Transplantation</brief_title>
  <official_title>The Role of Granulocyte-Colony Stimulating Factor (G-CSF) for Improving PELD Score and Nutritional Status in Pediatric Liver Cirrhosis Prior to Liver Transplantation Through Immunomodulation of Neutrophil, CD34+ Cell, TNF-α and IL-10</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fakultas Kedokteran Universitas Indonesia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr Cipto Mangunkusumo General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fakultas Kedokteran Universitas Indonesia</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the effect of human recombinant Granulocyte-Colony Stimulating Factor
      (G-CSF) in pediatric patients with liver cirrhosis with a control group. The study aims to
      observe improvement of (Pediatric End-stage Liver Disease) PELD score and nutritional status
      prior to liver transplantation procedure. In addition to the intervention, standard
      treatments for liver cirrhosis are also given for both groups. G-CSF is administered for 12
      times.

      Condition of disease:

      Pediatric patient aged 3 months to 12 years old Liver cirrhosis Undernourished / Severe
      malnutrition PELD score 10-25

      Intervention:

      Drug: Recombinant Human G-CSF

      Phase:

      Phase 3
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label randomized control trial conducted in Cipto Mangunkusumo Hospital, Jakarta,
      Indonesia, aimed to determine the effect of G-CSF to improve PELD score and nutritional
      status of pediatric patients with liver cirrhosis prior to liver transplantation. A total of
      52 pediatric patients with liver cirrhosis, malnutrition and PELD score between 10-25 will be
      collected and divided into intervention group and control group. The intervention group will
      be given a subcutaneous injection of G-CSF 5μg/kg/day for 5 days consecutively, followed by a
      single dose every 3 days up to 12 times throughout the trial. Additionally, both the
      intervention and control group receive standard liver cirrhosis treatment. Randomization is
      done using block randomization.

      The patients will be clinically monitored and evaluated for anthropometric changes (body
      weight, mid-arm circumference, mid-arm muscle circumference, and triceps skinfold thickness),
      complete blood count, absolute neutrophil count, liver function tests, cytokines (IL-10,
      TNF-α), Procalcitonin, hepatocyte growth factor (HGF), CD34+ cell count and PELD score
      (albumin, bilirubin, prothrombin and international normalized ratio values).

      Data analysis will be performed using IBM SPSS Statistics version 20.0.0.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PELD Score</measure>
    <time_frame>90 days</time_frame>
    <description>The scoring determines the individual's need for liver transplant. Calculation is based on an equation that incorporates the values of bilirubin serum, international normalized ratio, albumin and body growth measurement. Score ranges between 6 (low illness level) to 40 (severely ill).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anthropometric Changes</measure>
    <time_frame>90 days</time_frame>
    <description>Measurement of mid-arm circumference (MAC) will be obtained in centimeters and be plotted on the curve to observe changes in nutritional status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pro-inflammatory Marker</measure>
    <time_frame>30 days</time_frame>
    <description>Tumor necrosis factor alpha (TNF-α) cytokine level in the blood will be the parameter for pro-inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-inflammatory Marker</measure>
    <time_frame>30 days</time_frame>
    <description>Interleukin-10 (IL-10) cytokine level in the blood will be the parameter for anti-inflammatory marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Regeneration Marker</measure>
    <time_frame>30 days</time_frame>
    <description>hepatocyte growth factor (HGF) serum level will be the biochemical parameter for liver regeneration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Liver Cirrhoses</condition>
  <condition>Severe Malnutrition</condition>
  <condition>PELD</condition>
  <condition>Undernutrition</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of G-CSF with dose of 5μg/kg/day for 5 days consecutively, in addition to a single dose every 3 days up to 12 times, as well as liver cirrhosis standard regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Liver cirrhosis standard treatment only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF (Filgrastim)</intervention_name>
    <description>Contains 0,59 mg of acetate, 0,04 mg of polysorbate 80, 0,035 mg of sodium, 50 mg of sorbitol</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 3 months to 12 years old

          -  Conscious state

          -  Without the presence of fever (temperature: &lt;37,5°C)

          -  Decompensated liver cirrhosis

          -  Liver cirrhosis due to various etiology

          -  Undernourished or severe malnutrition

          -  PELD score between 10-25

        Exclusion Criteria:

          -  Malignancy (liver origin or other types)

          -  History of undergoing any organ transplantation procedure

          -  Acute liver failure

          -  Failure of any organ other than the liver

          -  Encephalopathy

          -  Severe infection such as bacterial peritonitis and pneumonia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tri Hening Rahayatri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Akmal Taher</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fakultas Kedokteran Universitas Indonesia</name>
      <address>
        <city>Jakarta</city>
        <state>Java</state>
        <zip>16424</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Fioredda F, Lanza T, Gallicola F, Riccardi F, Lanciotti M, Mastrodicasa E, Signa S, Zanardi S, Calvillo M, Dufour C. Long-term use of pegfilgrastim in children with severe congenital neutropenia: clinical and pharmacokinetic data. Blood. 2016 Oct 27;128(17):2178-2181. Epub 2016 Sep 12.</citation>
    <PMID>27621310</PMID>
  </reference>
  <reference>
    <citation>Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. Review.</citation>
    <PMID>28939926</PMID>
  </reference>
  <reference>
    <citation>Yang Q, Yang Y, Shi Y, Lv F, He J, Chen Z. Effects of Granulocyte Colony-Stimulating Factor on Patients with Liver Failure: a Meta-Analysis. J Clin Transl Hepatol. 2016 Jun 28;4(2):90-6. doi: 10.14218/JCTH.2016.00012. Epub 2016 Jun 15.</citation>
    <PMID>27350939</PMID>
  </reference>
  <reference>
    <citation>Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, Sakhuja P, Sarin SK. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012 Mar;142(3):505-512.e1. doi: 10.1053/j.gastro.2011.11.027. Epub 2011 Nov 23.</citation>
    <PMID>22119930</PMID>
  </reference>
  <reference>
    <citation>Chavez-Tapia NC, Mendiola-Pastrana I, Ornelas-Arroyo VJ, Noreña-Herrera C, Vidaña-Perez D, Delgado-Sanchez G, Uribe M, Barrientos-Gutierrez T. Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis. Ann Hepatol. 2015 Sep-Oct;14(5):631-41. Review.</citation>
    <PMID>26256891</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fakultas Kedokteran Universitas Indonesia</investigator_affiliation>
    <investigator_full_name>Tri Hening</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

